Shire Faces Consumer Antitrust Claims Over Adderall

Law360, New York (April 2, 2013, 7:56 PM EDT) -- Consumers in Pennsylvania and Florida hit Shire US Inc. with a pair of putative class actions this week accusing the pharmaceutical company of illegally stifling competition for Adderall XR, its blockbuster treatment for attention deficit hyperactivity disorder, with patent settlements and supply agreements with generic rivals.

Both cases focus on so-called pay-for-delay settlements that Shire inked with generics makers Teva Pharmaceuticals USA Inc. and Impax Laboratories Inc. to resolve allegations that the two companies' efforts to market a generic version of Adderall would violate Shire's patents....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re ADDERALL XR ANTITRUST LITIGATION


Case Number

1:12-cv-03711

Court

New York Southern

Nature of Suit

Anti-Trust

Judge

Victor Marrero

Date Filed

May 9, 2012


Case Title

NETWALL v. SHIRE U.S., INC. et al


Case Number

2:13-cv-01669

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Other Statutory Actions

Judge

GERALD J. PAPPERT

Date Filed

April 1, 2013


Case Title

Barba et al v. Shire US, Inc. et al


Case Number

1:13-cv-21158

Court

Florida Southern

Nature of Suit

Other Fraud

Judge

Joan A. Lenard

Date Filed

April 2, 2013

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.